NIH-Funding

Improving Outcomes for Disorders of Human Communication (R21 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 11:18
Funding Opportunity PA-18-288 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to improve the health outcomes for individuals with deafness and other communication disorders through effectiveness and health services research in the NIDCD mission areas of hearing, balance, smell, taste, voice, speech and language.
Categories: NIH-Funding

Improving Outcomes for Disorders of Human Communication (R01 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 11:15
Funding Opportunity PA-18-287 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to improve the health outcomes for individuals with deafness and other communication disorders through effectiveness and health services research in the NIDCD mission areas of hearing, balance, smell, taste, voice, speech and language.
Categories: NIH-Funding

Innovation Award for Mechanistic Studies to Optimize Mind and Body Interventions in NCCIH High Priority Research Topics (R33 Clinical Trial Required)

NIH Funding Announcements - Thu, 11/02/2017 - 11:02
Funding Opportunity PAR-18-115 from the NIH Guide for Grants and Contracts. Understanding the mechanisms by which complementary or integrative Mind and Body Interventions exert their clinical effects is critical for the development of optimized interventions that target specific conditions and disorders.
Categories: NIH-Funding

Phased Innovation Award for Mechanistic Studies to Optimize Mind and Body Interventions in NCCIH High Priority Research Topics (R61/R33 Clinical Trial Required)

NIH Funding Announcements - Thu, 11/02/2017 - 10:58
Funding Opportunity PAR-18-114 from the NIH Guide for Grants and Contracts. Understanding the mechanisms by which complementary or integrative Mind and Body Interventions exert their clinical effects is critical for the development of optimized interventions that target specific conditions and disorders.
Categories: NIH-Funding

Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:52
Funding Opportunity PAR-18-112 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors.
Categories: NIH-Funding

Studies at Periviable Gestation (R21 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:46
Funding Opportunity PA-18-097 from the NIH Guide for Grants and Contracts. The goals of this Funding Opportunity Announcement (FOA) are to focus on projects that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants.
Categories: NIH-Funding

Advancing Understanding, Prevention and Management of Infections Transmitted from Women to their Infants (R21 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:40
Funding Opportunity PA-18-092 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labor and delivery, and breastfeeding. NICHD is committed to supporting research that will increase scientific understanding of and treatments for high-priority perinatal infections.
Categories: NIH-Funding

Prescription Drug Abuse (R21 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:37
Funding Opportunity PA-18-076 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address these issues are encouraged across a broad range of methodological approaches including basic science, clinical, epidemiological, and health services research to define the extent of the problem of prescription drug abuse, to characterize this problem in terms of classes of drugs abused and combinations of drug types, etiology of abuse, and populations most affected (including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology). Studies on individual- and patient-level factors, prescriber factors, and/or health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative/hypnotics and anxiolytics. Researchers are further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed (e.g., pain, sleep disorder, anxiety disorder, obesity), and the environmental and individual factors contributing to abuse.
Categories: NIH-Funding

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:32
Funding Opportunity PA-18-075 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R21) applications from institutions/ organizations that propose to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for Substance Use Disorders (SUDs).
Categories: NIH-Funding

Behavioral and Integrative Treatment Development Program (R03 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:29
Funding Opportunity PA-18-074 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage investigators to propose discrete well-defined projects that can be completed within two years. Projects of interest fall within the research domain of behavioral or integrated (e.g., behavioral and pharmacological) interventions targeting: (a) substance abuse; (b) prevention of acquisition or transmission of HIV infection among individuals in drug abuse treatment; (c) promotion of adherence to drug abuse treatment, HIV and addiction medications; and (d) chronic pain. Specific examples include, but are not limited to studies focusing on: 1) Stage I intervention generation; 2) Stage I pilot or feasibility and both should include the development of putative moderators, mediators, and change mechanisms; (3) Stage I studies to generate or refine drug abuse treatment or adherence interventions; (4) Stage I research to boost effects and increase implementability of interventions with creative use of technology or through other means.
Categories: NIH-Funding

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:26
Funding Opportunity PA-18-073 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage investigators to propose discrete well-defined projects that can be completed within three years. Projects of interest fall within the research domain of behavioral or integrated (e.g., behavioral and pharmacological) interventions targeting: (a) substance abuse; (b) prevention of acquisition or transmission of HIV infection among individuals in substance abuse treatment; (c) promotion of adherence to substance abuse treatment, HIV and addiction medications; and (d) chronic pain. Specific examples include, but are not limited to studies focusing on: 1) Stage I intervention generation; 2) Stage I pilot or feasibility and both should include the development of putative targets/ moderators, mediators, and change mechanisms;(3) Stage I studies to generate or refine substance abuse treatment or adherence interventions for use in primary care; (4) Stage I research to boost effects and increase implementability of interventions with creative use of technology or other means.
Categories: NIH-Funding

Prescription Drug Abuse (R01 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:23
Funding Opportunity PA-18-058 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address these issues are encouraged across a broad range of methodological approaches including basic science, clinical, epidemiological, and health services research to define the extent of the problem of prescription drug abuse, to characterize this problem in terms of classes of drugs abused and combinations of drug types, etiology of abuse, and populations most affected (including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology). Studies on individual- and patient-level factors, prescriber factors, and/or health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative/hypnotics and anxiolytics. Researchers are further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed (e.g., pain, sleep disorder, anxiety disorder, obesity), and the environmental and individual factors contributing to abuse.
Categories: NIH-Funding

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:20
Funding Opportunity PA-18-056 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications from institutions/ organizations that propose to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for Substance Use Disorders (SUDs).
Categories: NIH-Funding

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:18
Funding Opportunity PA-18-055 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, optimize combinations, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities, in diverse settings; (2) drug abuse treatment and adherence interventions for use in primary care; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat chronic pain. Research of interest includes but is not limited to Stage II and Stage III efficacy research.
Categories: NIH-Funding

Studies at Periviable Gestation (R03 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:09
Funding Opportunity PA-18-053 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) focuses on projects that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants.
Categories: NIH-Funding

Studies at Periviable Gestation (R01 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:04
Funding Opportunity PA-18-036 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) focuses on projects that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants.
Categories: NIH-Funding

Advancing Understanding, Prevention, and Management of Infections Transmitted from Women to their Infants (R01 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 10:02
Funding Opportunity PA-18-031 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labor and delivery, and breastfeeding. NICHD is committed to supporting research that will increase scientific understanding of and treatments for high-priority perinatal infections.
Categories: NIH-Funding

Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 09:59
Funding Opportunity PA-18-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac specific common terminology criteria for adverse events (CTCAE).
Categories: NIH-Funding

Examination of Survivorship Care Planning Efficacy and Impact (R21 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 09:55
Funding Opportunity PA-18-012 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.
Categories: NIH-Funding

Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Optional)

NIH Funding Announcements - Thu, 11/02/2017 - 09:52
Funding Opportunity PA-18-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted under this FOA are encouraged to include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors.
Categories: NIH-Funding